Cerebral Infarction Clinical Trial
Official title:
Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study
Massive cerebral infarction is an ischemic stroke caused by complete blockage of the internal
carotid artery, middle cerebral artery, or their cortical branches. The widespread
infarction, pathological severity and high fatality rate associated with massive cerebral
infarction pose a major threat to affected patients. However, there is a lack of unified
diagnostic criteria. Many researchers use Adams' classification, in which massive cerebral
infarction is diagnosed when the following criteria are met: infarct size > 13 cm2; a major
brain-feeding artery is involved; the focal site affects more than two cerebral lobes;
infarct diameter line ≥ 3 cm in internal capsule of striatum.
Prolonged cerebral ischemia/reperfusion can induce complex secondary changes in brain tissue,
so the use of neuroprotective agents is very important. Remarkable progress has been made
over the last decade in understanding the protective effect of calcium antagonists against
cerebral ischemia. In particular, the liposoluble dihydropyridine Ca2+ antagonist nimodipine
selectively acts on cerebral vessels and neurons and can protect ischemic brain tissue,
providing a new way of treating ischemic cerebrovascular disease.
Preclinical and clinical tests have shown that nimodipine has a protective effect on ischemic
brain tissue, and indicate that patients should take the drug as soon as possible. However,
there are no reports of double-blind, randomized, controlled clinical trials addressing the
administration of nimodipine via intravenous drip within the time window for successful
treatment of acute massive cerebral infarction.
In the clinic, physicians are reluctant to use thrombolysis, Defibrase and anticoagulation
therapy because of the severity of symptoms, poor prognosis, risk of hemorrhage and high
fatality rate that occur with acute massive cerebral infarction. Nimodipine, as a selective
Ca2+ antagonist, is highly liposoluble, effectively crosses the blood-brain barrier,
selectively acts on intracranial blood vessels, and is an accepted neuroprotective agent that
can be applied in the clinic. The aim of the present study is to perform a double-blind,
randomized and controlled trial of the clinical efficacy and safety of nimodipine
administered as an intravenous drip in the early stages of acute massive cerebral infarction.
Patients will receive nimodipine within 3 days of infarction onset. We will closely monitor
the following: (1) Blood pressure and heart rate of the patient before treatment, since
nimodipine is contraindicated in patients with hypotension and low heart rate. Where blood
pressure is ≥ 100/80 mmHg and heart rate ≥ 60 BPM, nimodipine will be administered. (2) Speed
of infusion. This should not be too fast; we suggest 1-2 drops per minute initially,
increasing gradually until the drop in systolic pressure exceeds 10 mmHg. The average drip
speed should be 6-8 drops/minute, and the fastest drip speed 10 drops/minute. (3) During the
infusion, physicians should monitor adverse reactions such as headache, dizziness, flushing
or sweating. If any occur, the infusion speed must be reduced. If the patients remain
uncomfortable, nimodipine should be withdrawn. (4) Liver and kidney function should be
monitored throughout nimodipine administration.
Although nimodipine is relatively safe, there is still a risk of some adverse effects, such
as cardiovascular system reactions (blood pressure decreases, bradycardia, angina, and
atrioventricular block), headache, dizziness, edema, and liver and kidney dysfunction. It is
necessary to determine the optimal therapeutic time window and dose of nimodipine in
multi-center, large-scale clinical trials.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT00684515 -
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
|
Phase 2 | |
Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Terminated |
NCT01684462 -
The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT00386191 -
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
|
Phase 4 | |
Completed |
NCT00004734 -
Vitamin Therapy for Prevention of Stroke
|
Phase 3 | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Completed |
NCT02963545 -
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke
|
N/A | |
Completed |
NCT02511249 -
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
|
N/A | |
Completed |
NCT02101606 -
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
|
Phase 2 | |
Completed |
NCT01500421 -
Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)
|
Phase 2 | |
Completed |
NCT00829361 -
Stroke Telemedicine for Arizona Rural Residents Trial
|
N/A | |
Recruiting |
NCT01003470 -
Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study
|
Phase 2 | |
Terminated |
NCT00331890 -
ICTUS Study: International Citicoline Trial on Acute Stroke
|
Phase 3 | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03741400 -
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
|
N/A | |
Recruiting |
NCT04908241 -
Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL-RCT)
|
N/A |